J. Safra Sarasin Holding AG Has $1.30 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

J. Safra Sarasin Holding AG increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 309.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 2,303 shares of the biopharmaceutical company’s stock after purchasing an additional 1,741 shares during the period. J. Safra Sarasin Holding AG’s holdings in Regeneron Pharmaceuticals were worth $1,295,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $31,000. Traub Capital Management LLC bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $38,000. Berbice Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 87.5% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 2.6%

NASDAQ REGN opened at $751.13 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average of $758.43 and a 200-day moving average of $647.96. The company has a market cap of $78.94 billion, a PE ratio of 17.99, a PEG ratio of 2.01 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same period in the prior year, the firm posted $12.46 earnings per share. The company’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Truist Financial boosted their target price on Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Scotiabank upped their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research report on Monday, November 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Finally, Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $784.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.